Linqmed specializes in researching and developing radiopharmaceuticals for cancer treatment. It focuses on therapeutic and diagnostic drugs utilizing the radioisotope 64Cu.
Aeterlink
Series B in 2025
Aeterlink is a developer of innovative wireless power transfer technology aimed at creating a digital landscape devoid of wires. The company specializes in applying its advanced technology across various sectors, including factory automation, robotics, smart homes, and healthcare. By enabling wireless power transmission over distances, Aeterlink's solutions enhance efficiency and sustainability while improving safety by eliminating the hazards associated with traditional wiring. Their practical level technologies facilitate greater flexibility in device placement and operation, contributing to a more connected and streamlined environment across multiple industries.
JiMED develops a wireless embedded Brain-Computer Interface (BCI) system designed to read brain activity. The company offers an implantable device that uses artificial intelligence to interpret brain signals, enabling individuals with conditions like ALS to enhance communication and improve quality of life.
Neusignal Therapeutics
Series A in 2025
Neusignal Therapeutics is a biopharmaceutical company dedicated to developing small molecule drugs for the treatment of dementia and psychiatric disorders. Its primary focus lies in researching and developing therapeutic agents aimed at overcoming central nervous system diseases.
BlueWX is a technology company specializing in advanced weather forecast services. It leverages current research and artificial intelligence to enhance the precision of weather predictions, particularly for aviation. The company's services include detailed forecasts for flight routes, aiming to improve safety and operational efficiency for airlines and other aviation-related businesses. Additionally, BlueWX caters to industries that rely on accurate weather information for their operations.
DigitalArchi
Seed Round in 2025
DigitalArchi is a manufacturing company that specializes in producing sustainable architectural components. It uses large-scale 3D printing technology to create interior and exterior panels, as well as concrete formwork, from recycled plastic. This process not only helps reduce waste but also addresses labor shortages in the construction industry by enabling businesses to fabricate forms for concrete construction more efficiently.
Optieum Biotechnologies
Series A in 2025
Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company focused on developing innovative antibody-based therapies for cancer treatment. Utilizing its proprietary Eumbody System™, the company creates and detects single-chain variable fragment (scFv) product candidates that specifically target and modulate immune cell functions for oncology applications. By enhancing the proliferation capacity and longevity of single-chain variable CAR-T cells, Optieum aims to improve patient responses to advanced tumors while minimizing adverse effects. The company's commitment lies in delivering transformative therapies to patients suffering from severe diseases.
Japan Carbon Cycle Lab
Series A in 2024
Japan Carbon Cycle Lab is a technology company that focuses on the research and development of CO2 capture and recycling techniques.
elleThermo
Seed Round in 2024
elleThermo specializes in developing Semiconductor-Sensitised Thermal Cells (STCs), a technology designed to convert unused waste heat above room temperature into electricity.
Nihon Agri
Series C in 2024
Founded in Tokyo, Japan in 2016, Nihon Agri facilitates the export of Japanese agricultural products worldwide. It addresses challenges such as pricing, communication, and logistics to expand exports, satisfying both local farmers and global consumers.
Aeterlink
Series B in 2024
Aeterlink is a developer of innovative wireless power transfer technology aimed at creating a digital landscape devoid of wires. The company specializes in applying its advanced technology across various sectors, including factory automation, robotics, smart homes, and healthcare. By enabling wireless power transmission over distances, Aeterlink's solutions enhance efficiency and sustainability while improving safety by eliminating the hazards associated with traditional wiring. Their practical level technologies facilitate greater flexibility in device placement and operation, contributing to a more connected and streamlined environment across multiple industries.
Purmx is a pharmaceutical company that develops RNA nucleic acid medicine for therapeutic effects on intractable diseases.
Red Arrow Therapeutics
Seed Round in 2024
Red Arrow Therapeutics is a biotechnology company developing innovative cancer therapies. It focuses on systemic cytokine delivery, targeted intratumoral activation, and enhancing biological potency to maximize drug efficacy while minimizing toxicity.
Newmo is a technology company that specializes in sustainable local public transportation. It develops a ride-sharing service platform, enabling drivers to work flexibly using their free time, and providing passengers with a safe, secure, and comfortable user experience.
Axelspace
Series D in 2023
Founded in Tokyo, Japan in 2008, Axelspace designs, manufactures, and sells micro-satellites and related components for earth observation. Its primary projects include GRUS, Hodoyoshi-1, and UNIFORM, aiming to provide global daily monitoring at low cost.
Hedgehog MedTech
Series A in 2023
Hedgehog MedTech is a medical company specializing in digital therapeutics (DTx), which are programmable medical devices approved by pharmaceutical standards to assist in patient health management through mobile applications. The firm has developed a health application specifically aimed at treating headaches. This application utilizes a system that identifies and enhances behavioral patterns to alleviate symptoms. By delivering cognitive-behavioral therapy via the smartphone app, Hedgehog MedTech effectively connects users' daily lives with their medical care, particularly in the treatment of migraines.
Nanofiber Quantum Technologies
Convertible Note in 2023
Nanofiber Quantum Technologies is a research and manufacturing company focused on developing innovative hardware for quantum communications. The company specializes in creating quantum computers that utilize nanofibers and advanced engineering techniques. Its expertise encompasses quantum cryptography, quantum communications, and various technologies associated with quantum science aimed at practical applications. By integrating quantum computers into quantum communication networks, Nanofiber Quantum Technologies seeks to advance the field of quantum science and enhance secure communication methods for a range of clients.
Metagen Therapeutics
Series A in 2023
Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.
Heartseed
Series D in 2023
Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.
Metagen Therapeutics
Series A in 2023
Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.
Hedgehog MedTech
Seed Round in 2022
Hedgehog MedTech is a medical company specializing in digital therapeutics (DTx), which are programmable medical devices approved by pharmaceutical standards to assist in patient health management through mobile applications. The firm has developed a health application specifically aimed at treating headaches. This application utilizes a system that identifies and enhances behavioral patterns to alleviate symptoms. By delivering cognitive-behavioral therapy via the smartphone app, Hedgehog MedTech effectively connects users' daily lives with their medical care, particularly in the treatment of migraines.
Metagen Therapeutics
Seed Round in 2022
Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.
LIFESCAPES
Seed Round in 2022
LIFESCAPES is a research and manufacturing company specializing in brain-computer interface equipment, particularly for neurorehabilitation. The company's technology focuses on aiding stroke patients by enhancing brain plasticity, which allows individuals to overcome limitations and improve their quality of life. LIFESCAPES' devices are designed to extract and analyze brain-wave data in real-time, monitoring the activity of the functional compensation circuits in stroke patients. This innovative approach enables healthcare professionals to assist patients in regaining movement and addressing movement disorders, ultimately facilitating a more normal and fulfilling life for those affected.
K Pharma
Venture Round in 2022
K Pharma Inc is a pharmaceutical company focused on research, development, manufacturing, and marketing of innovative medical products, particularly in the field of neuro regenerative medicine. The company leverages induced pluripotent stem (iPS) cell technology to advance treatments for neurological conditions, including cerebral infarction and spinal cord injury. By integrating cutting-edge drug discovery methods with a commitment to developing effective medical solutions, K Pharma aims to address unmet needs in the healthcare sector. The company's efforts encompass the entire spectrum of pharmaceutical operations, from initial research through to the final product.
FingerVision
Seed Round in 2022
FingerVision specializes in developing advanced sensing devices and robot hands. The company leverages its tactile technology to enhance robots' movement capabilities, enabling automation in industries previously reliant on human labor for pick-and-place processes.
Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.
Cellusion
Venture Round in 2022
Cellusion is a regenerative medicine company developing induced pluripotent stem cell-derived corneal endothelial cells for the treatment of bullous keratopathy. The company focuses on research, development, manufacturing, and commercial supply of corneal endothelial cell substitutes for transplantation to restore corneal function and vision. Originating from Keio University, Cellusion aims to enable scalable, cell-based therapies by cultivating corneal endothelial cells from iPS sources and delivering them for surgical transplantation. Based in Tokyo, Japan, the company emphasizes advancing regenerative ophthalmology through cell-based therapies that offer less invasive treatment options for patients with endothelial corneal disease.
Luxonus is a medical device company focused on imaging technology that combines light and ultrasound to produce ultra-high-resolution 3D images of blood vessels and lymphatic networks. It develops a photoacoustic imaging platform designed for early detection and diagnosis of diseases, enabling clinicians to gain a comprehensive view of disease onset, progression, and recovery with non-invasive visualization and no radiation exposure.
Grace Imaging
Venture Round in 2021
Grace Imaging develops advanced fatigue measurement services using lactic acid sensing in sweat and MRI technologies.
Heartseed
Series C in 2021
Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.
Metagen Therapeutics
Seed Round in 2021
Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.
B dot Medical
Venture Round in 2021
B dot Medical specializes in developing ultra-compact proton beam cancer therapy equipment. Their system utilizes radiotherapy to precisely target tumors while minimizing damage to surrounding tissues, enabling more affordable proton cancer therapy.
Connect Japan
Venture Round in 2020
Connect Japan is developing services that connect people.
AdipoSeeds
Venture Round in 2020
AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.
Skygate Technologies
Seed Round in 2020
Founded in 2020, Skygate Technologies designs and develops a cloud ground station platform that enables efficient communication between satellites and the Earth. The company aims to make space data accessible via the web by building a network to deliver large volumes of data from observation satellites to the ground.
Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.
BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.
APB Co.
Venture Round in 2020
APB specializes in the research, development, manufacture, and sales of lithium-ion batteries. It uses polymer instead of metal for current collectors and coats active materials with dedicated polymer materials to enhance battery performance.
Kringle Pharma
Venture Round in 2020
Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.
Cellusion
Series A in 2020
Cellusion is a regenerative medicine company developing induced pluripotent stem cell-derived corneal endothelial cells for the treatment of bullous keratopathy. The company focuses on research, development, manufacturing, and commercial supply of corneal endothelial cell substitutes for transplantation to restore corneal function and vision. Originating from Keio University, Cellusion aims to enable scalable, cell-based therapies by cultivating corneal endothelial cells from iPS sources and delivering them for surgical transplantation. Based in Tokyo, Japan, the company emphasizes advancing regenerative ophthalmology through cell-based therapies that offer less invasive treatment options for patients with endothelial corneal disease.
Luxonus is a medical device company focused on imaging technology that combines light and ultrasound to produce ultra-high-resolution 3D images of blood vessels and lymphatic networks. It develops a photoacoustic imaging platform designed for early detection and diagnosis of diseases, enabling clinicians to gain a comprehensive view of disease onset, progression, and recovery with non-invasive visualization and no radiation exposure.
Synspective
Series A in 2019
Synspective specializes in developing and operating small synthetic aperture radar (SAR) satellites, providing SAR data and remote monitoring services. It caters to urban design, infrastructure, energy, insurance, finance sectors, and government agencies.
Motion Lib
Venture Round in 2019
Motion Lib, Inc. is a Japanese company specializing in the development of haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 and based in Kawasaki, the company was previously known as Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib creates advanced chips that estimate and calculate the repulsive force of objects being touched by robots, using the load force applied to the motor. This innovative technology enables robots to engage more effectively in various tasks, thereby expanding their operational capabilities and contributing to increased productivity across different sectors.
Instalimb
Venture Round in 2019
Instalimb, Inc. is a pioneering company based in Tokyo, Japan, specializing in the development of low-cost 3D printed prosthetics and orthotics. Leveraging advanced 3D-CAD, 3D printing, and machine learning technologies, Instalimb aims to revolutionize the prosthetics industry by significantly reducing production costs and delivery times. The company utilizes an innovative algorithm that enhances design efficiency, allowing for the creation of customized prosthetic devices tailored to individual needs. This cutting-edge approach not only makes prosthetics more accessible to amputees but also represents a significant advancement in the field of assistive technology. As the world's first business dedicated to 3D printed prostheses, Instalimb is committed to improving the quality of life for individuals requiring these essential devices.
Xenodata lab
Venture Round in 2019
Xenodata Lab, Co., Ltd., founded in 2012 and based in Tokyo, Japan, specializes in artificial intelligence-driven data analysis. The company develops a platform that transforms unstructured data from financial reports into structured, table-format data, enhancing accuracy and accessibility for users. By focusing on economic forecasts and financial document analysis, Xenodata Lab enables businesses to effectively interpret and utilize information following financial results announcements. The company aims to advance the financial industry through innovative technology and the efficient processing of data, emphasizing the potential of AI to enhance human decision-making in this sector.
Luxonus
Venture Round in 2019
Luxonus is a medical device company focused on imaging technology that combines light and ultrasound to produce ultra-high-resolution 3D images of blood vessels and lymphatic networks. It develops a photoacoustic imaging platform designed for early detection and diagnosis of diseases, enabling clinicians to gain a comprehensive view of disease onset, progression, and recovery with non-invasive visualization and no radiation exposure.
Himuka AM Pharma
Venture Round in 2018
Himuka AM Pharma is a pharmaceutical company dedicated to the research and development of Adrenomedullin derivatives. Founded in 2017, it focuses on creating drug candidates based on the bioactive peptide adrenomedullin for mucosal healing and clinical remission.
BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.
CureApp, Inc. is a Tokyo-based digital health startup founded in 2014, specializing in the development of mobile applications aimed at treating various diseases. The company is recognized for its innovative approach to healthcare, particularly with its nicotine addiction treatment app launched in February 2015, which was developed in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp’s platform not only promotes clinical trials but also focuses on providing real-time, personalized guidance for lifestyle diseases through a cloud-based system that analyzes daily activity logs. This enables patients to manage their conditions more effectively, addressing health issues that are often overlooked by traditional medications and devices.
Tsubota Lab
Venture Round in 2018
Tsubota Laboratory Inc focuses on research and development aimed at preventing and treating various eye conditions, including myopia, dry eye, and presbyopia. The company is dedicated to creating evidence-based solutions and develops both pharmaceuticals and medical devices to address these eye diseases and related systemic disorders. Through its innovative approach, Tsubota Laboratory strives to improve eye health and enhance the quality of life for individuals affected by these conditions.
Institution for a Global Society
Corporate Round in 2017
Institution for a Global Society specializes in providing innovative assessment solutions to educational institutions and businesses. Its offerings include GROW Academy, DxGROW, Ai GROW, and GROW360, utilizing appropriate technology ethically to foster sustainable learning and development.
IDAC Theranostics
Venture Round in 2017
IDAC Theranostics, Inc. is a biotechnology company based in Tokyo, Japan, established in 2012. It focuses on the research, development, and production of pharmaceutical products aimed at treating cancer, graft-versus-host disease (GVHD), inflammatory diseases, and other conditions. The company specializes in creating drug therapies for diseases that traditionally require only symptomatic treatment. IDAC Theranostics collaborates with Japanese academic institutions, pharmaceutical companies, and international organizations to advance its research and development efforts, striving to provide innovative solutions for patients with unmet medical needs.
Motion Lib
Venture Round in 2017
Motion Lib, Inc. is a Japanese company specializing in the development of haptic technology aimed at enhancing collaboration between humans and robots. Founded in 2016 and based in Kawasaki, the company was previously known as Undou Sekkei Kenkyuusho Limited before rebranding in April 2017. Motion Lib creates advanced chips that estimate and calculate the repulsive force of objects being touched by robots, using the load force applied to the motor. This innovative technology enables robots to engage more effectively in various tasks, thereby expanding their operational capabilities and contributing to increased productivity across different sectors.
Generic Solution
Venture Round in 2017
Founded in Tokyo, Japan in 2006, Generic Solution specializes in software distribution services. The company offers GS8 software for information retrieval and machine learning, along with distributed computing services, data model design, and data analysis to help clients achieve measurable outcomes.
Bonx
Venture Round in 2017
BONX Inc. is a Tokyo-based company that specializes in the design and development of wearable communication devices for outdoor sports enthusiasts. Established in 2014, BONX has created the BONX Grip, a Bluetooth earpiece designed to withstand water and shock, allowing athletes engaged in activities such as snowboarding, cycling, stand-up paddleboarding, and fishing to communicate seamlessly. The device supports group conversations, enabling users to stay connected with friends while participating in leisure and sporting activities. BONX sells its products online, catering to a niche market of outdoor sports participants seeking reliable communication solutions.
CureApp, Inc. is a Tokyo-based digital health startup founded in 2014, specializing in the development of mobile applications aimed at treating various diseases. The company is recognized for its innovative approach to healthcare, particularly with its nicotine addiction treatment app launched in February 2015, which was developed in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp’s platform not only promotes clinical trials but also focuses on providing real-time, personalized guidance for lifestyle diseases through a cloud-based system that analyzes daily activity logs. This enables patients to manage their conditions more effectively, addressing health issues that are often overlooked by traditional medications and devices.
Quan
Venture Round in 2017
Quan Inc., founded in 2011 and based in Tokyo, Japan, specializes in developing character-driven content for smartphone applications and web platforms. The company offers a diverse portfolio of over 500 characters, including Betakkuma, Sugar Cubs, and Business Fish, which are utilized in various messaging applications and social games, primarily targeting markets in Japan and Southeast Asia. In addition to character development, Quan Inc. provides global content distribution services and creates illustrations and stamps for chat apps. The company also engages in public relations and advertising, offering services such as market research, translation, and game management to enhance user engagement and promote its content effectively.
AdipoSeeds
Seed Round in 2017
AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.
Kringle Pharma
Venture Round in 2016
Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.
SENSY
Venture Round in 2016
Founded in Tokyo, Japan in 2011, SENSY specializes in AI technology designed to understand human sensibilities. It analyzes data from various sources like images, text, and user actions to enable personalized marketing strategies.